In a patient with bipolar disorder on lithium and hypothyroidism on levothyroxine who uses cannabis (marijuana), are there any drug interactions or clinical considerations?

Drug Interactions Between Cannabis, Lithium, and Levothyroxine in Bipolar Disorder

There are no clinically significant direct pharmacokinetic interactions between cannabis, lithium, and levothyroxine, but cannabis may exacerbate psychiatric symptoms in bipolar disorder and lithium commonly causes hypothyroidism requiring levothyroxine treatment. 1, 2

Cannabis and Lithium: Psychiatric Considerations

• Cannabis use poses significant psychiatric risks in bipolar disorder including mood destabilization, increased risk of manic episodes, and worsening of psychotic symptoms, regardless of lithium therapy. 1

• Cannabis inhibits cytochrome P450 enzymes (CYP3A4, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19), but lithium is renally eliminated and not metabolized by these enzymes, so no direct pharmacokinetic interaction occurs. 1

• The primary concern is additive CNS effects: cannabis causes dizziness, confusion, drowsiness, and mood changes that may compound lithium's neurological side effects and complicate mood monitoring. 1

• Cannabis may trigger tachycardia and orthostatic hypotension, which can be problematic as lithium itself may cause T-wave changes, bradycardia, and AV-block. 1

Lithium and Levothyroxine: Expected Interaction

• Lithium causes hypothyroidism in approximately 20% of patients and goiter in up to 40%, making levothyroxine co-prescription common and expected in this population. 2

• Continue both medications concurrently—levothyroxine effectively treats lithium-induced hypothyroidism without requiring lithium discontinuation. 2

• Lithium increases thyroid autoimmunity if present before therapy, and hypothyroidism risk increases with female sex and longer lithium treatment duration. 2, 3

• Monitor thyroid function (TSH, free T4) every 3-6 months in all patients on lithium, regardless of whether they are taking levothyroxine. 4, 5

• Subclinical hypothyroidism occurs in 7.1% of lithium-treated patients, and thyroid dysfunction may manifest as altered T4 to T3 conversion in 47.6% of patients. 6

Cannabis and Levothyroxine: No Direct Interaction

• No evidence suggests cannabis affects levothyroxine absorption, metabolism, or efficacy. 1

• Levothyroxine is not metabolized by cytochrome P450 enzymes inhibited by cannabis, eliminating pharmacokinetic interaction concerns. 1

Clinical Management Algorithm

Immediate Assessment

• Document cannabis use pattern: frequency (times per day), amount (grams of smoked cannabis or mg of THC/CBD), route of administration, and duration of use. 1

• Assess for cannabis-related psychiatric symptoms: paranoia, severe confusion, mood destabilization, or signs of cannabis use disorder (using more than expected, difficulty cutting back). 1

• Check current lithium level (therapeutic range 0.6-1.2 mEq/L for maintenance) and recent thyroid function tests (TSH, free T4). 4

Cannabis-Specific Interventions

• Counsel patient on psychiatric risks: cannabis may worsen bipolar symptoms, trigger manic episodes, and increase risk of developing cannabis use disorder (10% of chronic users). 1

• If cannabis use exceeds 1.5 g/day smoked, 300 mg/day CBD oil, or 20 mg/day THC oil, consider increased risk for cannabinoid hyperemesis syndrome and withdrawal symptoms upon cessation. 1

• Cannabis withdrawal symptoms (irritability, restlessness, anxiety, sleep disturbance) may mimic bipolar symptoms and complicate mood assessment. 1

Lithium Monitoring

• Maintain lithium levels every 3-6 months, along with renal function (creatinine, BUN) and thyroid function (TSH, free T4). 4, 5

• Educate patient that lithium requires consistent hydration—cannabis-induced dry mouth may reduce fluid intake, potentially increasing lithium levels and toxicity risk. 1

Levothyroxine Management

• Administer levothyroxine on an empty stomach, 30-60 minutes before breakfast, separate from lithium dosing to optimize absorption. 1

• Recheck TSH 6-8 weeks after any levothyroxine dose adjustment to ensure adequate thyroid replacement. 1

• Monitor for signs of overtreatment (angina, arrhythmia, increased cardiac wall thickness, bone mineral density loss) as levothyroxine overdosing occurs in 25% of treated patients. 1

Psychiatric Stability Maintenance

• Do not discontinue lithium—it remains the primary mood stabilizer with FDA approval for bipolar disorder maintenance therapy. 1

• If anxiety or sleep disturbance emerges (potentially cannabis-related), consider adding trazodone 50-100 mg at bedtime rather than benzodiazepines, as trazodone provides sedation without mood destabilization risk. 4

• Avoid antidepressant monotherapy—if depressive symptoms develop, ensure lithium is maintained and consider adding lamotrigine (with slow titration) rather than attributing symptoms solely to cannabis use. 5, 7

Common Pitfalls to Avoid

• Do not attribute all mood symptoms to cannabis use—bipolar disorder itself causes mood fluctuations, and lithium-induced hypothyroidism can mimic or worsen depressive symptoms. 2, 8

• Do not stop lithium due to hypothyroidism—simply add or adjust levothyroxine dosing. 2

• Do not assume cannabis is "safe" because it lacks direct drug interactions—the psychiatric risks in bipolar disorder are substantial and may lead to hospitalization or mood destabilization. 1

• Do not overlook cannabis hyperemesis syndrome in patients with cyclic nausea and vomiting, especially if cannabis use exceeds 4 times per week for over a year—this mimics cyclic vomiting syndrome and is relieved by hot showers. 1

• Do not prescribe benzodiazepines for cannabis-related anxiety without clear limits (lorazepam 0.25-0.5 mg PRN, maximum 2-3 times weekly)—tolerance and dependence develop rapidly. 7

Summary of Monitoring Requirements

• Lithium level: every 3-6 months (target 0.6-1.2 mEq/L for maintenance) 4
• Thyroid function (TSH, free T4): every 3-6 months 4, 5
• Renal function (creatinine, BUN): every 3-6 months 4
• Mood symptoms: assess at every visit for signs of mania, depression, or cannabis-related destabilization 5
• Cannabis use pattern: document frequency and amount at each visit to identify escalation or development of cannabis use disorder 1